Medibank is facing another class action investigation over a massive data breach that left the personal information of almost 10 million customers exposed, just days after criminals began publishing sensitive customer health data.
Novartis and and generic drug maker Pharmacor have resolved litigation over the Swiss pharmaceutical giant’s patents for blockbuster MS drug Gilenya.
A judge has ordered Smile Direct Club and its Australian unit to pay a $3.5 million penalty and reimburse customers for misleading them into believing they would be reimbursed by their insurers for the dental care company’s costly teeth straighteners.
A class action investigation over the data breach that exposed the personal information of almost 10 million Medibank customers is underway, with two law firms teaming up to probe whether the private health insurer is liable for damages.
Medibank will not pay a ransom to a criminal who stole the data of 9.7 million customers, saying it would encourage extortion.
A top orthopaedic surgeon and former NSW Australian of the year has sued Channel Nine and Fairfax for defamation over a recent 60 Minutes episode and articles that appeared in The Age and the Sydney Morning Herald.
Swiss pharmaceutical company Biogen and Australian generic drug maker Pharmacor have dropped their claims against one another in a lawsuit over the patent for MS drug Tecfidera. In an October 14 order by Federal Court Justice Helen Rofe, Biogen’s infringement claims and Pharmacor’s cross-claims seeking to invalidate the lucrative patent were discontinued by consent without…
A judge has stayed a class action on behalf of 6,000 women allegedly injured by defective pelvic mesh devices after Astora Women’s Health filed for bankruptcy in the United States, but questioned how the company had suddenly come to have no assets.
Medibank’s woes worsened Wednesday as the insurer revealed data for all 4 million of its current and former customers had been accessed during a cyberattack after initially reporting no customer data had been exposed.
A class action against Bayer over its allegedly defective Essure contraceptive devices has admonished the drug manufacturer’s bid to shield emails considered privileged in similar US litigation, arguing “thoughts and prayers” are needed to sustain the claim.